Prognostic Value of Immune Checkpoint Molecules in Breast Cancer

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2020 Jul 1

PMID 32602545

Citations 62

Authors

Jun Fang

Feng Chen

Dong Liu

Feiying Gu

Zhigang Chen

Yuezhen Wang

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint blockade treatments bring remarkable clinical benefits to fighting several solid malignancies. However, the efficacy of immune checkpoint blockade in breast cancer remains controversial. Several clinical trials of immune checkpoint blockades focused on the effect of CTLA4 and PD1/PDL1 checkpoint inhibitors on breast cancer. Only a small portion of patients benefited from these therapies. Here we systematically investigated the expression of 50 immune checkpoint genes, including ADORA2A, LAG-3, TIM-3, PD1, PDL1, PDL2, CTLA-4, IDO1, B7-H3, B7-H4, CD244, BTLA, TIGIT, CD80, CD86, VISTA, CD28, ICOS, ICOSLG, HVEM, CD160, LIGHT, CD137, CD137L, OX40, CD70, CD27, CD40, CD40LG, LGALS9, GITRL, CEACAM1, CD47, SIRPA, DNAM1, CD155, 2B4, CD48, TMIGD2, HHLA2, BTN2A1, DC-SIGN, BTN2A2, BTN3A1, BTNL3, BTNL9, CD96, TDO, CD200 and CD200R, in different subtypes of breast cancer and assessed their prognostic value. The results showed that the expression patterns of these 50 immune checkpoint genes were distinct in breast cancer. High expression of B7-H3 mRNA was significantly associated with worse overall survival (OS), especially in patients with luminal A and luminal B breast cancer. The mRNA expression levels of TIM-3, ADORA2A, LAG3, CD86, CD80, PD1 and IDO1 had no relationship with OS in breast cancer. High expression levels of CTLA-4 and TIGIT were correlated with favorable prognosis in breast cancer. Interestingly, we observed that B7-H3 expression was negatively correlated with the efficacy of cyclophosphamide (CTX). In summary, our study suggested that B7-H3 has potential prognostic value in breast cancer and is a promising target for immune therapy.

Citing Articles

PRDX2 induces tumor immune evasion by modulating the HDAC3-Galectin-9 axis in lung adenocarcinoma cells.

Dong Y, Cheng A, Zhou J, Guo J, Liu Y, Li X J Transl Med. 2025; 23(1):81.

PMID: 39825365 PMC: 11740609. DOI: 10.1186/s12967-024-05888-z.

Identification of a novel immune checkpoint-related gene signature predicts prognosis and immunotherapy in breast cancer and experiment verification.

Yin K, Guo Y, Wang J, Guo S, Zhang C, Dai Y Sci Rep. 2024; 14(1):31065.

PMID: 39730892 PMC: 11680899. DOI: 10.1038/s41598-024-82266-1.

CD27 as a Diagnostic Biomarker and Its Role in Immune Heterogeneity and Predicting Clinical Drug Responses in Hashimoto's Thyroiditis.

Dong Y, Bao G Pharmgenomics Pers Med. 2024; 17:535-550.

PMID: 39717528 PMC: 11664005. DOI: 10.2147/PGPM.S487091.

High CTLA-4 gene expression is an independent good prognosis factor in breast cancer patients, especially in the HER2-enriched subtype.

Montoyo-Pujol Y, Ponce J, Delgado-Garcia S, Martin T, Ballester H, Castellon-Molla E Cancer Cell Int. 2024; 24(1):371.

PMID: 39523362 PMC: 11552348. DOI: 10.1186/s12935-024-03554-4.

Baseline sLAG-3 levels in Caucasian and African-American breast cancer patients.

Swede H, Ridwan S, Strandberg J, Salner A, Sporn J, Kuo L Breast Cancer Res Treat. 2024; 208(1):193-200.

PMID: 39230627 DOI: 10.1007/s10549-024-07455-y.

References

Liu Z, Zhang W, Phillips J, Arora R, McClellan S, Li J . Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. Oncogene. 2018; 38(1):88-102. PMC: 6318029. DOI: 10.1038/s41388-018-0407-9. View

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

Nanda R, Chow L, Dees E, Berger R, Gupta S, Geva R . Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016; 34(21):2460-7. PMC: 6816000. DOI: 10.1200/JCO.2015.64.8931. View

Kakimi K, Karasaki T, Matsushita H, Sugie T . Advances in personalized cancer immunotherapy. Breast Cancer. 2016; 24(1):16-24. DOI: 10.1007/s12282-016-0688-1. View

Carthon B, Wolchok J, Yuan J, Kamat A, Ng Tang D, Sun J . Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010; 16(10):2861-71. PMC: 2919850. DOI: 10.1158/1078-0432.CCR-10-0569. View

Parra K, Valenzuela P, Lerma N, Gallegos A, Reza L, Rodriguez G . Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br J Cancer. 2017; 116(3):324-334. PMC: 5294484. DOI: 10.1038/bjc.2016.429. View

Yang J, Hughes M, Kammula U, Royal R, Sherry R, Topalian S . Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30(8):825-30. PMC: 2134980. DOI: 10.1097/CJI.0b013e318156e47e. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

van den Eertwegh A, Versluis J, van den Berg H, Santegoets S, Jeroen A van Moorselaar R, van der Sluis T . Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13(5):509-17. DOI: 10.1016/S1470-2045(12)70007-4. View

10.

Nirschl C, Drake C . Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013; 19(18):4917-24. PMC: 4005613. DOI: 10.1158/1078-0432.CCR-12-1972. View

11.

Zhang P, Chen Z, Ning K, Jin J, Han X . Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells. Biochem Biophys Res Commun. 2017; 490(3):1132-1138. DOI: 10.1016/j.bbrc.2017.07.001. View

12.

Rugo H, Delord J, Im S, Ott P, Piha-Paul S, Bedard P . Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clin Cancer Res. 2018; 24(12):2804-2811. DOI: 10.1158/1078-0432.CCR-17-3452. View

13.

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

14.

Weber J, ODay S, Urba W, Powderly J, Nichol G, Yellin M . Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008; 26(36):5950-6. DOI: 10.1200/JCO.2008.16.1927. View

15.

Jia Y, Yang B, Wen L, Mu W, Wang Z, Cheng B . Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. Aging (Albany NY). 2019; 11(2):501-522. PMC: 6366990. DOI: 10.18632/aging.101756. View

16.

Tu L, Guan R, Yang H, Zhou Y, Hong W, Ma L . Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer. 2019; 147(2):423-439. DOI: 10.1002/ijc.32785. View

17.

Liu C, Liu J, Wang J, Liu Y, Zhang F, Lin W . B7-H3 expression in ductal and lobular breast cancer and its association with IL-10. Mol Med Rep. 2012; 7(1):134-8. DOI: 10.3892/mmr.2012.1158. View

18.

Pizon M, Schott D, Pachmann U, Pachmann K . B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients. Int J Oncol. 2018; 53(5):2289-2299. DOI: 10.3892/ijo.2018.4551. View

19.

Dirix L, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H, Forero-Torres A . Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2017; 167(3):671-686. PMC: 5807460. DOI: 10.1007/s10549-017-4537-5. View

20.

Lee Y, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H . Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017; 27(8):1034-1045. PMC: 5539354. DOI: 10.1038/cr.2017.90. View